Palvella Therapeutics, Inc.
Strafford, PA
- UEI
- KTH1B7KWRCN9
- CAGE
- 8AT89
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 353 W Lancaster Ave #200, Strafford, PA 19087, USA
- Website
- palvellatx.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Selva: a multicenter, phase 3 baseline-controlled study evaluating the safety and efficacy of PTX-022 in the treatment… | FDA Office of Acquisition and Grant Services | $1,128,394 |
Quick answers
What is Palvella Therapeutics, Inc.'s UEI?
Palvella Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is KTH1B7KWRCN9.
What is Palvella Therapeutics, Inc.'s CAGE code?
Palvella Therapeutics, Inc.'s CAGE code is 8AT89.
Where is Palvella Therapeutics, Inc. located?
Palvella Therapeutics, Inc.'s physical address in SAM.gov is 353 W Lancaster Ave #200, Strafford, PA 19087, USA.
Is Palvella Therapeutics, Inc. registered in SAM.gov?
Yes. Palvella Therapeutics, Inc.'s SAM.gov registration is active through October 5, 2027.
What is Palvella Therapeutics, Inc.'s most recent federal award?
Palvella Therapeutics, Inc.'s most recent federal grant award is Selva: a multicenter, phase 3 baseline-controlled study evaluating the safety and efficacy of PTX-022 in the treatment… (R01FD008196), from FDA Office of Acquisition and Grant Services, on September 20, 2024.
On GovTribe
See Palvella Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors